Aodi Huang, Xia Xu, Lin Tang, Lifang Huang, Jun Li, Xue Zhang, Jiajie Liu, Yang Zhou, Bingling Zhang, Lei Wang, Qian Zhang, Zemei Zhou, Yu Wang, Xiaoqi Wang, Qianqian Liu, Siyu Liu, Zundong Yin, Fuzhen Wang
DTaP-HBV-IPV-Hib hexavalent vaccine has been used in high-income countries for many years to prevent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and invasive Haemophilus influenzae type b disease. Currently, no hexavalent vaccines have been approved for use in China. Evidence of parental acceptance and interest in hexavalent vaccines can help policy makers and manufacturers make decisions about entering the vaccine market and the immunization program in China. We measured parental acceptance and willingness-to-pay (WTP) for a hexavalent vaccine to provide such evidence...
December 31, 2024: Human Vaccines & Immunotherapeutics